Nova

Founding Chair of the Mass Casualty Commission's Progress Monitoring Committee appointed

Retrieved on: 
Wednesday, May 31, 2023
Linda, FPT, Survivor, Citizenship, Refugee, Justice, Violence, Commission, PMC, Federal, National Action Plan to Combat Human Trafficking, Government, Parliament, Organization, 2020 Nova Scotia attacks, Dive (Belgian band), Nova, Government of Canada, Grief, Founding, Hunting, Central Nova, Public security, Radio, First Nations, Parliamentarian, GBV, Federation, Trauma, National Commission on the Status of Women, Responses to the COVID-19 pandemic in April 2020, Mental health, Woman, RCMP, Safety, Chair, Property management

Today, the federal Minister of Public Safety, the Honourable Marco Mendicino, and Nova Scotia Attorney General and Minister of Justice, the Honourable Brad Johns, announced the appointment of Linda Lee Oland as Founding Chair of the Progress Monitoring Committee (PMC).

Key Points: 
  • Today, the federal Minister of Public Safety, the Honourable Marco Mendicino, and Nova Scotia Attorney General and Minister of Justice, the Honourable Brad Johns, announced the appointment of Linda Lee Oland as Founding Chair of the Progress Monitoring Committee (PMC).
  • Recognizing the devastating impact the mass casualty event has had on families and communities, the Founding Chair will ensure the work of the PMC are guided by trauma informed and victim centric principles.
  • In appointing Justice Oland, we continue to act upon the recommendations put forward by the Mass Casualty Commission.
  • The Mass Casualty Commission was officially established after the Government of Canada and province of Nova Scotia each issued an Order in Council on October 21, 2020.

Bishop Fox Adds Cybersecurity Product and Engineering Veteran as Chief Product Officer

Retrieved on: 
Wednesday, May 31, 2023
Cosmos, Software as a service, Defense, National security, Culture, Nova, Engineering, Tonkin, Gigaom, CPO, Software, Management

PHOENIX, May 31, 2023 (GLOBE NEWSWIRE) -- Bishop Fox , the leading authority in offensive security, today announced the addition of Kevin Tonkin as the company’s first Chief Product Officer (CPO).

Key Points: 
  • PHOENIX, May 31, 2023 (GLOBE NEWSWIRE) -- Bishop Fox , the leading authority in offensive security, today announced the addition of Kevin Tonkin as the company’s first Chief Product Officer (CPO).
  • With more than 20 years of software and engineering experience, Tonkin brings proven leadership in building product organizations and bringing innovative products to market.
  • Tonkin joins Bishop Fox at a critical juncture as the company looks to extend its market leadership in offensive security.
  • Prior to that, he was the VP of product engineering for Coalfire, where he rebuilt and scaled the engineering team from 6 to more than 60 cross-functional members, encompassing product management, design, and customer success functions.

Ameriwest Lithium Provides Corporate Update and Announces Appointment of New CFO and a New Marketing Agreement

Retrieved on: 
Thursday, May 25, 2023
Lithium, Exercise, Business development, CSE, University, Eli, Private, Marketing, Technical report, Little Smoky Valley, Property, Geology, FSE, Metallurgy, Accounting, Canadian Institute of Mining, Metallurgy and Petroleum, Petroleum, Private placement agent, Nova, Report, QP, Acquisition, Soil, National instrument, NI, ROW, Mining, OTC, CPA, Local marketing agreement, National Instrument 43-101, GFOP, News, Technical, Interior design, Security (finance), Uranium mining, Cryptocurrency

Ameriwest CEO, Mr. David Watkinson, stated “Ameriwest transformed into a lithium exploration and development company in 2021.

Key Points: 
  • Ameriwest CEO, Mr. David Watkinson, stated “Ameriwest transformed into a lithium exploration and development company in 2021.
  • Funds from the Private Placement are being utilized for the Company’s general corporate and working capital purposes during the next 12 months.
  • The Company is also pleased to announce the recent appointment of Robert Hill as the Company’s Chief Financial Officer.
  • On January 31, 2023, Ameriwest announced it had completed a mineral property option agreement with Nova Lithium Corp. (“Nova”).

Daniel Nova Named to Eversource Board of Trustees

Retrieved on: 
Friday, May 26, 2023
Energy, Utilities, Oil, Gas, Internet, Compensation, Electricity, American Repertory Theater, United Company, General partnership, Whittier Street Health Center, Highland Capital Partners, Marketing, Wind, Adviser, Silicon, Eversource Energy, Nova, Partner, Trustee, CMG, Water, Natural gas, Harvard Business School, General partner, Computer science, NYSE, Management, Renewable energy, Science, Newsweek, Boston College

Eversource Energy (NYSE: ES) today announced the election of Daniel J. Nova to its Board of Trustees effective June 1, 2023.

Key Points: 
  • Eversource Energy (NYSE: ES) today announced the election of Daniel J. Nova to its Board of Trustees effective June 1, 2023.
  • Nova was also appointed as a member of the Compensation and Finance Committees effective June 1, 2023.
  • Nova is currently general partner at Highland Capital Partners, a global venture capital firm with offices in Boston, Silicon Valley and San Francisco.
  • “Dan brings exceptional history and experience in finance, IT and investment management,” said Eversource Chairman, President and CEO Joe Nolan.

Studio Shed Introduces New Turnkey, Built-to-Code Accessory Dwelling Units (ADUs)

Retrieved on: 
Thursday, May 11, 2023
Playing card suit, Housing, ADU, LVT, Secondary suite, Foot, Nova, Dream, Collection, FSC, HGTV, Summit, Interior design, Cabinetry

LOUISVILLE, Colo., May 11, 2023 /PRNewswire-PRWeb/ -- As the demand for Accessory Dwelling Units (ADUs) continues to rise and zoning regulations for the popular housing solution lift in neighborhoods across the country, Studio Shed, the prefabricated modular home industry leader since 2008, today announced the debut of a new collection of four curated ADU designs in an effort to streamline and ease the permitting and building process for its customers.

Key Points: 
  • The new product offerings feature sizes ranging from a studio to one- and two-bedroom units, complete with interior layouts, finishes and Express Permit Plan Sets.
  • "This is an exciting milestone for Studio Shed," said Jeremy Nova, the company's cofounder and creative director.
  • The customer manages the permitting process, and Studio Shed ships the final product flat-packaged as a kit once permitted.
  • The new Studio Shed ADUs are available online at https://www.studio-shed.com/models/ and start at $87,197.

Nova Reports First Quarter 2023 Results

Retrieved on: 
Thursday, May 11, 2023
GAAP, Nova, Investment, Growth, Video game

Based on current estimates, management expects:

Key Points: 
  • Based on current estimates, management expects:
    Total revenues for the first quarter of 2023 were $132.2 million, a decrease of 13% compared with the fourth quarter of 2022 and a decrease of 1% compared with the first quarter of 2022.
  • Gross margin in the first quarter of 2023 was 58%, compared with 55% in the fourth quarter of 2022 and 56% in the first quarter of 2022.
  • Operating expenses in the first quarter of 2023 were $41.5 million, compared with $45.5 million in the fourth quarter of 2022 and $37.6 million in the first quarter of 2022.
  • On a non-GAAP basis, the Company reported net income of $39.1 million, or $1.23 per diluted share, in the first quarter of 2023.

iTrack™ Canaloplasty to be Featured in Numerous Scientific Presentations at the ASCRS 2023 Annual Meeting

Retrieved on: 
Thursday, May 4, 2023
Medical Devices, Health, Other Health, General Health, Optical, Biotechnology, Glaucoma, IOP, Refractive surgery, Comparison, Food and Drug Administration, ASCRS, Intraocular pressure, SDCC, American Society of Cataract and Refractive Surgery, Nova, Patient, Cataract, FDA, Society, Food, Pharmaceutical industry, Employment agency

A summary of the iTrack™ scientific programming at the ASCRS is outlined below:

Key Points: 
  • A summary of the iTrack™ scientific programming at the ASCRS is outlined below:
    Location: San Diego Convention Center (SDCC), Upper Level, Room 5B
    Location: San Diego Convention Center (SDCC), Upper Level, Room 5B
    Location: San Diego Convention Center (SDCC), Upper Level, Room 5B
    Location: San Diego Convention Center (SDCC) - Upper Level, Room 5A
    Location: San Diego Convention Center (SDCC) - Upper Level, Room 1B
    Location: San Diego Convention Center (SDCC) - Upper Level, Room 1B
    Location: San Diego Convention Center (SDCC) - Upper Level, Room 1B
    Location: San Diego Convention Center (SDCC) - Upper Level, Room 1B
    Location: San Diego Convention Center (SDCC) - Upper Level, Room 1B
    “36-Month Comparison of Outcomes of Canaloplasty: Standalone or Combined with Cataract Surgery and across All Grades of Glaucoma Severity”
    “We are proud that our world-leading canaloplasty technology, iTrack™, will be front and center at the ASCRS 2023.
  • The iTrack-rich podium at this year’s meeting is proof that canaloplasty is increasingly recognized as a highly versatile and effective treatment in lowering IOP in mild-moderate glaucoma patients.
  • The ASCRS Annual Meeting is one of the world’s largest gatherings of anterior segment surgeons.
  • All educational content of the ASCRS annual meeting is planned by its program committee.

Nova Launches Brandguard and BrandGPT to Bring Brand Safety to Generative AI

Retrieved on: 
Wednesday, May 3, 2023
AI, Avocado, Nova, Brain, Life, Marketing, Medical device, Sales

NEW YORK, May 3, 2023 /PRNewswire/ -- Today Nova , a leader in automated revenue generation using generative AI, is announcing the beta availability of Brandguard , and BrandGPT .

Key Points: 
  • NEW YORK, May 3, 2023 /PRNewswire/ -- Today Nova , a leader in automated revenue generation using generative AI, is announcing the beta availability of Brandguard , and BrandGPT .
  • BrandGPT provides a chat interface over BrandGuard™, Nova's innovative product that understands your brand to help you enforce and protect brand consistency in a world of generative AI.
  • In a world where generative AI is growing so fast, but is making so many errors, Brandguard is a key part of your brand safety kit.
  • Nova was founded in 2022 to bring automated ad campaign generation to enterprises, and quickly realized the challenges of generative AI.

Pizza Nova’s That’s Amore Pizza for Kids is back with a month-long fundraiser in support of Variety – the Children’s Charity of Ontario

Retrieved on: 
Tuesday, May 2, 2023
COVID-19, Variety, the Children's Charity, Child, Nova, Pizza Nova, Kingston Road, Fast food, Online shopping, Variety

Toronto, May 02, 2023 (GLOBE NEWSWIRE) -- Pizza Nova, Southern Ontario’s premium pizza brand, launches its 24th annual fundraising campaign in support of Variety – the Children’s Charity of Ontario.

Key Points: 
  • Toronto, May 02, 2023 (GLOBE NEWSWIRE) -- Pizza Nova, Southern Ontario’s premium pizza brand, launches its 24th annual fundraising campaign in support of Variety – the Children’s Charity of Ontario.
  • “Every child has unique gifts, talents and abilities,” says Domenic Primucci, president of Pizza Nova.
  • “Pizza Nova is one of our largest and most committed corporate donors,” said Karen Stintz, president and CEO of Variety.
  • To learn more about the fundraiser or to place your order for pizzas and a dozen dips, visit pizzanova.com .

Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial

Retrieved on: 
Tuesday, April 18, 2023
Mental Health, Research, Neurology, Clinical Trials, Alternative Medicine, Health, Pharmaceutical, Other Science, Science, Psilocybin, NOVA, CSE, Therapy, Spectrum, IIA, FRA, Well-being, Messenger, MEDI, KGK, FXS, Disorder, Nova, ASD, OTC, Phase, Health Canada, SQ2, NEO, Safety, Fragile X syndrome, Pharmaceutical industry

The 28-day study will test the safety and efficacy of Nova Mentis’ proprietary psilocybin drug (NM-1001) for the treatment of FXS and is one of the first Health Canada approved studies allowing participants to take home psilocybin for dosing every other day.

Key Points: 
  • The 28-day study will test the safety and efficacy of Nova Mentis’ proprietary psilocybin drug (NM-1001) for the treatment of FXS and is one of the first Health Canada approved studies allowing participants to take home psilocybin for dosing every other day.
  • Nova Mentis and KGK have partnered to conduct the Phase IIA clinical trial, which is being carried out at the KGK facility in London, Ontario, Canada.
  • This 10-person, open-label study will assess repetitive, oral microdose psilocybin therapy for FXS.
  • “KGK Science is eager to begin testing the efficacy of microdosing psilocybin in this cutting-edge clinical trial.